

04-19-04

Patent Application
Attorney Docket No.27721A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner of Patents, Box 1450, P.O. Box 1450, Alexandria, VA 22313-1450 on this 16 day of April 2004.

By

(Signature of person mailing)
Andrea E. Dorigo

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mickelson, J. :

APPLICATION NO.: 10/706,555 : Examiner:

FILING DATE: November 12, 2003 : Group Art Unit: 1614

TITLE: PYRAZINE COMPOUNDS AS CRF :
MODULATORS

Mail Stop DD

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). The listing of the references on the PTO-FB-A820 form is not intended to represent or imply that these references are prior art to the above-captioned application. Applicants reserve the right to challenge the status of any reference so listed or otherwise identified as prior art.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).


Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: _____

April 16 2004



Andrea E. Dorigo
Attorney for Applicant(s)
Reg. No. 47,532

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212)773 -1898

INFORMATION DISCLOSURE CITATION

(Use separate sheets if necessary)

ATTY. DOCKET NO. PC27721

SERIAL NO. 10/706,555

APPLICANT Mickelson, J.

FILING DATE November 12, 2003

GROUP 1614

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---------------------|----|-----------------|---|---|---|---|---|---|-------|---------------------|-------|----------|----------------------------------|
| | 1) | 6 | 5 | 8 | 9 | 9 | 4 | 7 | 07/03 | Hamanaka et al. | 514 | 183 | |
| | 2) | 6 | 0 | 4 | 3 | 2 | 6 | 0 | 03/00 | Chen et al. | 514 | 348 | |
| | 3) | 5 | 8 | 7 | 2 | 1 | 3 | 6 | 03/97 | Anthony et al. | 514 | 341 | |
| | 4) | 5 | 8 | 8 | 0 | 1 | 4 | 0 | 04/97 | Anthony, Neville J. | 514 | 333 | |
| | 5) | 5 | 8 | 8 | 3 | 1 | 0 | 5 | 03/97 | Anthony, Neville J. | 514 | 277 | |

FOREIGN PATENT DOCUMENTS


| DOCUMENT NUMBER | | | | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|-----------------|-----|---|---|---|---|---|---|---|-------|---------|-------|----------|-------------|----|
| | | | | | | | | | | | | | YES | NO |
| ' | 6) | 1 | 0 | 9 | 7 | 7 | 0 | 9 | 10/00 | EPO | A61K | A61K | | |
| ' | 7) | 9 | 7 | 3 | 5 | 9 | 0 | 1 | 03/97 | WO | C08G | C09D | | |
| ' | 8) | 9 | 8 | 2 | 9 | 1 | 1 | 9 | 12/97 | WO | A61K | C07D | | |
| ' | 9) | 9 | 7 | 3 | 6 | 8 | 8 | 6 | 01/97 | WO | C07D | A61K | | |
| | 10) | 0 | 1 | 6 | 0 | 8 | 0 | 6 | 08/01 | WO | C07D | | | |
| | 11) | 0 | 1 | 0 | 0 | 8 | 3 | 8 | 12/02 | WO | C07D | A61K | | |
| | 12) | 9 | 7 | 3 | 6 | 8 | 9 | 8 | 04/97 | WO | C07D | A61K | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|-----|--|
| 13) | J. Rivier et al., <i>Proc. Natl. Acad. Sci (USA)</i> 80:4851 (1983) |
| 14) | W. Vale et al., <i>Science</i> 213:1394 (1981) |
| 15) | W. Vale et al., <i>Rec. Prog. Horm. Res.</i> 39:245 (1983); F. Koob, <i>Persp. Behav. Med.</i> 2:39 (1985) |
| 16) | E.B. De Souza et al., <i>J. Neurosci.</i> 5:3189 (1985)]. |
| 17) | J.E. Blalock, <i>Physiological Reviews</i> 69:1 (1989) |
| 18) | J.E. Morley, <i>Life Sci.</i> 41:527 (1987) |
| 19) | E.B. De Souza, <i>Hosp. Practice</i> 23:59 (1988) |
| 20) | The Merck Manual of Diagnosis and Therapy, 16 'h edition (1992) |
| 21) | C.B. Nemeroff et al., <i>Science</i> 226:1342 (1984) |
| 22) | C.M. Banki et al., <i>Ain. J. Psychiatry</i> 144:873 (1987) |
| 23) | R.D. France et al., <i>Biol. Psychiatry</i> 23:86 (1988) |

| | | | |
|--|--|-------------------------------|-----------------------|
| INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) | | ATTY. DOCKET NO. PC27721 | SERIAL NO. 10/706,555 |
| | | APPLICANT Mickelson, J. | |
| | | FILING DATE November 12, 2003 | GROUP 1614 |

| | |
|-----|--|
| 24) | M. Arato et al., <i>Biol. Psychiatry</i> 25:355 (1989) |
| 25) | C.B. Nemeroff et al., <i>Arch. Gen. Psychiatry</i> 45:577 (1988) |
| 26) | P.W. Gold et al., <i>Anz. J. Psychiatry</i> 141:619 (1984) |
| 27) | F. Holsboer et al., <i>Psychoneuroendocrinology</i> 9:147 (1984); |
| 28) | P.W. Gold et al., <i>The American J. Of Psych.</i> 141:5 (1984) |
| 29) | R.M. Sapolsky, <i>Arch. Gen. Psychiatry</i> 46:1047 (1989) |
| 30) | Grigoriadis et al., <i>Neuropsychopharmacology</i> 2:53 (1989) |
| 31) | D. R. Britton et al., <i>Life Sci.</i> 31:363 (1982) |
| 32) | C.W. Berridge and A.J. Dunn <i>Regid. Peptides</i> 16:83 (1986) |
| 33) | C.W. Berridge and A.J. Dunn <i>Horm. Behav.</i> 21:393 (1987) |
| 34) | <i>Brain Research Reviews</i> 15:71 (1990) |
| 35) | K.T. Britton et al., <i>Psychopharmacology</i> 86:170 (1985) |
| 36) | K.T. Britton et al., <i>Psychopharmacology</i> 94:306 (1988) |
| 37) | N.R. Swerdlow et al., <i>Psychopharmacology</i> 88:147 (1986) |
| 38) | G.F. Koob and K.T. Britton, In: <i>Corticotropin-Releasing Factor: Basic and Clinical Studies of a 15 Neuropeptide</i> , E.B. De Souza and C.B. Nemeroff eds., CRC Press p.221 (1990) |
| 39) | Design of Prodrugs, H. Bundgaard, ea.. Elsevier, 1985 |
| 40) | A Textbook of Drug Design and Development, Krogsgaard-Larsen and H. Bundgaard, ea. Chapter 5 "Design and Applications of Prodrugs" p.1 13-191, 1991 |
| 41) | Advanced Drug Delivery Reviews, H. Bundgaard, 8, p.1-38, 1992 |
| 42) | <i>Journal of Pharmaceutical Sciences</i> , 77, p. 285, 30 1988 |
| 43) | <i>Chem. Pharm. Bull.</i> , N. Kakeya et al, 32, p. 692, 1984 |
| 44) | Pro-drugs as Novel Delivery Systems, T. Higuchi and V. Stella, Vol. 14 of the A.C.S. Symposium Series, and Bioreversible Carriers in Drug Design, Edward B. Roche, ea.. American Pharmaceutical Association and Peruamon Press, 1987 |
| 45) | G. Battaglia et al., <i>Synapse</i> 1:572 (1987) |
| 46) | J.A. Miller <i>Tetrahedron Lett.</i> 1998,39,7275. |
| 47) | S. L Buchwald, <i>J. Org. Chem.</i> 2000, 1158. |
| 48) | Brockman et al., <i>Methods in Enzymology</i> , K Widder et al., Ed., Academic Press 42, p.309 (1985) |

| | | |
|--|-------------------------------|-----------------------|
| INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i> | ATTY. DOCKET NO. PC27721 | SERIAL NO. 10/706,555 |
| | APPLICANT Mickelson, J. | |
| | FILING DATE November 12, 2003 | GROUP 1614 |
| <div> <div>  </div> <div> EXAMINER </div> <div> DATE CONSIDERED </div> </div> | | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | |

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE